United States Patent 9,951,080 (Drug Patent): Scope, Claim-by-Claim Coverage, and Patent Landscape Implications
What does US 9,951,080 claim, in practical terms?
US 9,951,080 is directed to a single, tightly defined solid-state material and downstream product forms built from it. The protection concentrates on (i) a specific crystalline form (a freebase hemihydrate) and (ii) compositions where that form is present at defined quality thresholds, plus (iii) characterization-driven fallback claim sets (XRPD/DSC/TGA/moisture sorption/lattice parameters) that make design-around via “different solid” harder.
The claims pivot around the same active molecule:
(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
and the same designated solid-state form:
- Freebase Hydrate Form C
- Claim 1 also recites it generically as a crystalline hemihydrate of that active.
The patent then builds coverage tiers:
- Material claims (crystalline hemihydrate with specific characterization)
- Solid-state composition claims (quality % thresholds)
- Pharmaceutical composition claims (carrier + dose deliverable amounts)
- Process claims (mixing API/form with carrier)
Claim set map: what is protected and how broad is each layer?
A. Core solid form protection (claims 1–12)
These are the “anchor” claims that define the protected material.
Claim 1
- A crystalline hemihydrate of the specified active molecule.
This is broadest at the “form class” level: any crystalline hemihydrate meeting the definition is within scope, even before XRPD/DSC/TGA refinement.
Claims 2–5
- Add XRPD peak-defined versions of the hemihydrate at ~25 °C with monochromatic Kα1 radiation.
- The claims differ by which additional peaks are required beyond a baseline set.
Shared baseline across multiple dependent XRPD claims
- Peak at 13.4 ± 0.2° (2θ)
- Peak at 15.1 ± 0.2° (2θ)
- Peak at 21.7 ± 0.2° (2θ)
Extra peak requirements vary:
- Claim 3 includes 17.0 ± 0.2°
- Claim 4 includes 20.9 ± 0.2°
- Claim 5 includes 15.5 ± 0.2°, 17.0 ± 0.2°, 20.9 ± 0.2° (plus the shared baseline peaks)
Claims 6–12
- Further constrain the same material by:
- Claim 6: explicitly equates to Freebase Hydrate Form C
- Claim 7: XRPD “substantially as shown in FIG. 3C” (evidence-based match rather than only enumerated peaks)
- Claim 8: TGA “substantially as shown in FIG. 4E”
- Claim 9: DSC “substantially as shown in FIG. 5C”
- Claim 10: DSC endotherm between ~120 °C and ~170 °C when heated at 10 °C/min
- Claim 11: moisture sorption isotherm “substantially as shown in FIG. 6B”
- Claim 12: lattice specification: orthorhombic, P212121, with a ~12.7 Å, b ~13.1 Å, c ~22.6 Å
Practical reading
- Claim 1 gives an initial foothold on “crystalline hemihydrate.”
- The dependent claims create multiple evidentiary pressure points (XRPD, DSC, TGA, moisture sorption, unit cell and space group). In enforcement, this structure supports different proof routes if the accused product shows partial overlap of peaks or exhibits the same thermal and lattice behavior.
B. Solid-state quality claims (claims 13–15 and 21–23)
These claims widen from the pure form to mixtures where that form is the dominant solid.
Claims 13–15 (solid state form)
- Claim 13: a composition comprising a solid state form, wherein the solid state form is Freebase Hydrate Form C
- Claim 14: at least ~75% by weight of Form C
- Claim 15: at least ~95% by weight of Form C
Claims 21–23 (crystalline hemihydrate quality)
- Claim 21: composition where the solid state form is the crystalline hemihydrate of claim 2 (which is the XRPD-refined variant)
- Claim 22: at least ~75% by weight of that crystalline hemihydrate
- Claim 23: at least ~95% by weight of that crystalline hemihydrate
Practical reading
- The patent anticipates routine formulation realities: commercial solids often include minor polymorph or hydrate populations.
- The thresholds at 75% and 95% create two enforcement bands:
- moderate adulteration still risks infringement
- “near pure” Form C is directly targeted.
C. Pharmaceutical composition claims (claims 16–20 and 24–28)
These translate the solid-state form into dosage units and marketed product forms.
Claims 16–20 (pharmaceutical composition using Form C)
- Claim 16: pharmaceutical composition comprising Form C + pharmaceutically acceptable carrier
- Claims 17–20: carrier composition amount sufficient to deliver 7.5 mg, 15 mg, 30 mg, 45 mg of the active (as specified)
Claims 24–28 (pharmaceutical composition using crystalline hemihydrate of claim 2)
- Claim 24: pharmaceutical composition comprising the crystalline hemihydrate of claim 2 + carrier
- Claims 25–28: dose deliverables at 7.5 mg, 15 mg, 30 mg, 45 mg.
Practical reading
- The presence of multiple dose deliverable amounts suggests a product line strategy (or a dose-ranging development program) where the same solid form is intended to be used across marketed strengths.
- Any formulation using the protected form and falling into these dose deliverable amounts is exposed, regardless of excipient selection, so long as the claim language is met.
D. Process claims (claims 29–30)
Claim 29: process for preparing the pharmaceutical composition of claim 16
- combining Form C with the carrier.
Claim 30: process for preparing the pharmaceutical composition of claim 24
- combining the crystalline hemihydrate with the carrier.
Practical reading
- The process claims are limited and “mixing-centric,” which can still matter if a generic or contract manufacturer uses the protected form in the final step.
How does the claim dependency structure drive enforceability?
US 9,951,080 uses an increasingly specific chain:
- Generic form (crystalline hemihydrate) → XRPD peak sets → explicit “Form C” naming → microscopy-like match to figures → thermal behavior → moisture behavior → lattice/space group.
This gives multiple “lock points” for claim interpretation and proof:
- If the accused solid disputes peak assignments, the patentee can also rely on DSC/TGA/moisture/lattice claim hooks.
- If the accused solid has differing minor peaks, “substantially as shown in FIG.” dependent claims can still align through qualitative match rather than purely enumerated peak lists.
What is the scope for design-around? (where it may fail)
Based on the claim structure alone, the main design-around routes are:
- Use a different hydrate level (e.g., non-hemihydrate hydrate or anhydrous forms)
- Use a non-crystalline or different crystallographic polymorph/solid state form
- Use Form C but ensure the solid-state mixture drops below the required weight thresholds (75% or 95%)
- Use different thermal and XRPD behavior (to avoid satisfying the defined characterization constraints)
However, the patent’s breadth makes some “partial” changes insufficient:
- The presence of Claim 1 (crystalline hemihydrate) limits how far one can go if any “hemihydrate crystalline” material is used.
- The explicitly named Form C (Claim 6) and the lattice/space group definition (Claim 12) reduce ambiguity around “what Form C is.”
- The XRPD peak families (Claims 2–5) include multiple ways to satisfy dependent claim requirements. An accused material with the baseline peaks may still land in one or more dependent claim sets depending on which additional peaks appear.
Where does the patent sit in the broader US patent landscape for solid-state forms?
Without the rest of the record (e.g., continuation family, earliest priority, related publications, and other listed patents), a complete landscape cannot be built solely from claim text. What can be concluded from the claim architecture is the likely role of this patent within a family:
- It is a solid form patent focused on a single hydrate form (Form C).
- It is likely part of a broader set of patents covering:
- other polymorphs/hydrates/free bases/salts
- process crystallization methods
- formulation and dose regimens (the presence of multiple dose deliverables suggests this).
If there are earlier US filings in the same family, this document likely functions as the specific claim-set for the Form C hemihydrate and compositions using it, rather than a base-method-of-treatment patent.
Key claim elements and numeric constraints (for freedom-to-operate review)
The following are the “hard” technical parameters repeatedly used to define scope:
XRPD peaks at ~25 °C (monochromatic Cu Kα1 implied by “Kα1” language)
- Common baseline in dependent XRPD claims:
- 13.4 ± 0.2°
- 15.1 ± 0.2°
- 21.7 ± 0.2°
- Additional peak sets:
- Claim 3 adds 17.0 ± 0.2°
- Claim 4 adds 20.9 ± 0.2°
- Claim 5 adds 15.5 ± 0.2°, 17.0 ± 0.2°, 20.9 ± 0.2°
Crystallography / lattice (Claim 12)
- Orthorhombic lattice
- Space group: P212121
- Unit cell:
- a ~12.7 Å
- b ~13.1 Å
- c ~22.6 Å
Thermal characterization (Claims 8–10)
- TGA profile: “substantially as shown in FIG. 4E” (Claim 8)
- DSC profile: “substantially as shown in FIG. 5C” (Claim 9)
- DSC endotherm: 120 °C to 170 °C at 10 °C/min (Claim 10)
Moisture sorption (Claim 11)
- Moisture sorption isotherm profile “substantially as shown in FIG. 6B”
Composition thresholds (weight % of Form)
- Solid state Form C compositions:
- ≥ 75% by weight (Claim 14)
- ≥ 95% by weight (Claim 15)
- Crystalline hemihydrate compositions (relative to claim 2 variant):
- ≥ 75% by weight (Claim 22)
- ≥ 95% by weight (Claim 23)
Dose deliverables in pharmaceutical compositions
- 7.5 mg (Claims 17, 25)
- 15 mg (Claims 18, 26)
- 30 mg (Claims 19, 27)
- 45 mg (Claims 20, 28)
Landscape actions for business teams (what to check)
A practical freedom-to-operate review, guided strictly by the claim set, should focus on:
- Material identity mapping
- Determine whether the candidate API solid matches hemihydrate and whether it is Freebase Hydrate Form C.
- Test-method alignment
- Validate XRPD conditions (25 °C, monochromatic Kα1) against the asserted peak windows.
- Orthorhombic lattice confirmation
- Check whether the space group and unit cell parameters align to P212121 with a ~12.7 Å, b ~13.1 Å, c ~22.6 Å.
- Thermal behavior
- Confirm DSC endotherm presence in 120 °C to 170 °C at 10 °C/min.
- Formulation composition
- For any mixture, confirm whether it meets the ≥75% or ≥95% Form C thresholds.
- Dose/strength alignment
- If marketed or developed strengths correspond to 7.5, 15, 30, 45 mg, ensure the solid-state form used is not within scope.
Key Takeaways
- US 9,951,080 is a solid-state form patent anchored on a crystalline hemihydrate that is explicitly Freebase Hydrate Form C.
- The claim set pairs broad identity coverage (Claim 1 and Claim 6) with multiple characterization-based dependent claim hooks (XRPD peak lists, DSC/TGA/moisture profiles, and lattice parameters).
- The patent extends protection from the material into solid mixtures (≥75% and ≥95% by weight) and into pharmaceutical compositions at 7.5/15/30/45 mg deliverable strengths.
- Design-around must avoid using a solid that meets the hemihydrate + Form C identity, or avoid meeting the composition weight thresholds and characterization matches that drive the dependent claims.
FAQs
1) Does the patent cover only the pure crystalline hemihydrate or also mixtures?
It covers mixtures via claims requiring the solid state form to be present at ≥75% and ≥95% by weight (Claims 14–15 and 22–23).
2) What analytical methods are central to proving infringement?
XRPD (peak windows at ~25 °C with Kα1), DSC (including a 120–170 °C endotherm at 10 °C/min), TGA, moisture sorption isotherm, and lattice parameters (P212121, a ~12.7 Å, b ~13.1 Å, c ~22.6 Å) (Claims 2–5, 8–12).
3) Are there multiple ways to capture the same crystalline hemihydrate in the dependent claims?
Yes. The XRPD-dependent claims define overlapping peak sets (Claims 2–5) and also allow figure-based “substantially as shown” coverage (Claims 7–11).
4) Does the patent restrict formulation excipients or only the solid form and dose?
The claims require the presence of the protected form and a pharmaceutically acceptable carrier, plus dose deliverable amounts for dependent strength claims. Excipient selection is not otherwise constrained in the provided claims text (Claims 16–20, 24–28).
5) Do the process claims matter for manufacturing exposure?
Yes. They cover processes that include combining the protected form with a pharmaceutically acceptable carrier to prepare the pharmaceutical composition (Claims 29–30).
References
- US Patent 9,951,080 (claims as provided by user).
